Thanks wop though weirdly enough I find the estimate that the share price might more than double underwhelming. I cannot fathom how a company with a disruptive product like ColoSTAT in a market sector measured in tens of billions of dollars could be bought for as little as some hundred million dollars. Blood tests are preferred over stool tests by 70% of those surveyed and ColoSTAT is 35% more accurate than FIT ... what else is there to know?
I haven't rolled out this saying for a while but I hope it is pertinent to biosciences in this instance:
“In economics, things take longer to happen than you think they will, and then they happen faster than you thought they could.”
― Rudiger Dornbusch
Updated Analysts Report Just Out, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $24.85M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 10.0¢ | $5.166K | 51.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 164195 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.43pm 18/10/2024 (20 minute delay) ? |
| RHY (ASX) Chart |